glp-1 and parkinson's disease A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes obesity, including cardiovascular and neurodegenerative disorders Neuroprotective Actions of Glucagon-Like Peptide-1

Do oral peptides need the same storage care

Unilateral ureteral obstruction as a model to investigate fibrosis-attenuating treatments

Tirzepatide's SURMOUNT-5 head-to-head vs semaglutide (2025): Zepbound demonstrated 47% greater relative weight loss vs Wegovy in a direct Phase 3b comparison the most commercially significant clinical trial result in the obesity market, directly challenging Novo Nordisk's market leadership

Regular check-ins help track progress and make sure the medication continues to support your overall health

We encourage anyone considering medical weight loss to engage in open dialogue with their healthcare team